长期的糖皮质激素治疗可以迅速导致骨质疏松,其严重性依赖于剂量和治疗时间,它引起的骨副作用并没有安全的界限.糖皮质激素性骨质疏松症的发病机制可能是其损害肠道的钙吸收, 严重抑制成骨形成, 刺激骨细胞的凋亡.

[1] American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis:2001 update. 2001. doi:10.1002/1529-0131(200107)44:7&lt, 1496::AID-ART271&gt, 3.0.CO, 2-5
[2] SOUCY E, BELLAMY N, ADACHI J D. A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists, 2000
[3] van STAA T P, LEUFKENS H G, ABENHAIM L. Use of oral corticosteroids and risk of fractures. 2003. doi:10.1359/jbmr.2000.15.6.993
[4] Fujita K, KASAYAMA S, HASHIMOTO J. Inhaled corticosteroids reduce bone mineral density in early postmenopausal but not premenopausal asthmatic women. 2001. doi:10.1359/jbmr.2001.16.4.782
[5] CARBONARE L D, ARLOT M E, CHAVASSIEUX P M. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. 2001. doi:10.1359/jbmr.2001.16.1.97
[6] 邹丽宜, 吴铁. 糖皮质激素与骨质疏松. 中国骨质疏松杂志2003(2). doi:10.3969/j.issn.1006-7108.2003.02.026
[7] HAHN T J, HALSTEAD L R, BARAN D T. Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. 2001. doi:10.1210/jcem-52-1-111
[8] 李裕明, 徐琳, 陈璐璐. 糖皮质激素所致骨质疏松与维生素D受体基因型相关性的初步研究. 中华风湿病学杂志2003(10)
[9] Hofbauer L C, GORI F, RIGGS B L. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells:potential paracrine mechanisms of glucocorticoid-induced osteoporosis. 2001. doi:10.1210/en.140.10.4382
[10] AARON J E, FRANCIS R M, PEACOCK M. Contrasting microanatomy of idiopathic and corticosteroid-induced osteoporosis, 2002
[11] Ledro C D, TORRES D Y, LARIA L C. Biochemical markers and bone densitometry in inflammatory bowel disease, 2000
[12] DOLAN A L, MONIZ C, DASGUPTA B. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica, 2002
[13] Prince M, BANERJEE C, JAVED C. Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts. 2001(3). doi:10.1002/1097-4644(20010301)80:3&lt, 424::AID-JCB160&gt, 3.0.CO, 2-6
[14] 董友, 郭昭庆, 宋存理. PPARγ在糖皮质激素诱导的骨质疏松中的表达. 中国比较医学杂志2003(3). doi:10.3969/j.issn.1671-7856.2003.03.007
[15] WEINSTEIN R S, JILKA R L, PARFITT A M. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids:potential mechanisms of their deleterious effects on bone, 2003
[16] Pearce G, TABENSKY D A, DELMAS P D. Corticosteroid-induced bone loss in men. 2003
[17] 万学峰, 牛文光, 惠艳. 糖皮质激素性骨质疏松的治疗进展. 临床荟萃2004(18). doi:10.3969/j.issn.1004-583X.2004.18.042